Identifying drugs that may help extend human lifespan
Official title: Integrative Cross Species Analysis for Longevity Drug Target Identification
Funded at Translational Genomics Research Inst · NIH-11144139 · Data updated 2026-11-12
This study is looking for ways to help people age more slowly and stay healthier longer by finding new drug targets and understanding the biology of aging, which could lead to better treatments for age-related diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | September 15, 2019 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $390,000 |
| NIH project number | 3UH3AG064706-05S1 |
| Project ID | NIH-11144139 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults interested in interventions that may promote healthy aging and longevity.
✕Less likely to help
Patients who are not aging or do not have age-related health concerns may not receive benefits from this research.
What this research studies
This research investigates potential drug targets that could slow the aging process and delay age-related diseases. By analyzing data from both human studies and cross-species research, the project aims to discover biological markers and pathways that contribute to longevity. The approach includes examining metabolites and proteins in various tissues to understand healthy aging better. Patients may benefit from insights that could lead to new interventions aimed at promoting longer, healthier lives.
Why it matters
Potential benefit: If successful, this research could lead to the development of medications that enhance longevity and improve overall health in aging individuals.
How similar studies have gone: Previous research has shown promise in identifying longevity-enhancing compounds in non-human species, but this approach is still relatively novel in humans.
Where this research is happening
-
Translational Genomics Research Inst
Phoenix, United States Active
Researchers
- Principal investigator: Schork, Nicholas Joseph — Translational Genomics Research Inst
- Study coordinator: Schork, Nicholas Joseph
Related research
Other NIH-funded projects on the same topics.
-
CLU's role in Alzheimer's disease pathogenesis
Researchers are studying how the CLU gene may drive brain changes in Alzheimer's disease and how targeting CLU could lead to safer treatments.
-
How glioblastoma changes across the tumor and over time during treatment
This work maps how glioblastoma tumors shift their cell types and interactions during and after treatment to find weaknesses that could help people with recurrent GBM.
-
Understanding how early changes in lungs lead to progressive fibrotic disease
This grant studies the cells and genes involved in starting and advancing pulmonary fibrosis to uncover why some people progress to severe disease.
-
Integrative Analysis Core for Longevity and Dementia Research
A broad, shared analysis resource aims to bring together multiple studies on aging, longevity, and Alzheimer’s disease to better understand how genetics and other factors influence healthy aging.
-
Understanding Why Some People Age Well Despite Alzheimer’s and Related Dementias
Researchers are building patient-derived cell models to study why some people resist or slow down dementia and how aging affects brain cells, with a focus on Alzheimer’s Disease and related disorders.
-
Drugs that slow aging and extend healthy years
A research project aims to find and test medicines that could slow aging and help people stay healthier longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.